Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Common Equity: 2022-2025

Historic Common Equity for bioAffinity Technologies (BIAF) over the last 3 years, with Sep 2025 value amounting to $8.9 million.

  • bioAffinity Technologies' Common Equity rose 185.23% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year increase of 185.23%. This contributed to the annual value of $2.6 million for FY2024, which is 46.41% down from last year.
  • Latest data reveals that bioAffinity Technologies reported Common Equity of $8.9 million as of Q3 2025, which was up 516.75% from -$2.1 million recorded in Q2 2025.
  • bioAffinity Technologies' 5-year Common Equity high stood at $12.6 million for Q3 2022, and its period low was -$2.1 million during Q2 2025.
  • Over the past 3 years, bioAffinity Technologies' median Common Equity value was $4.9 million (recorded in 2023), while the average stood at $4.7 million.
  • Within the past 5 years, the most significant YoY rise in bioAffinity Technologies' Common Equity was 185.23% (2025), while the steepest drop was 162.22% (2025).
  • Quarterly analysis of 4 years shows bioAffinity Technologies' Common Equity stood at $11.0 million in 2022, then plummeted by 56.03% to $4.9 million in 2023, then slumped by 46.41% to $2.6 million in 2024, then spiked by 185.23% to $8.9 million in 2025.
  • Its Common Equity was $8.9 million in Q3 2025, compared to -$2.1 million in Q2 2025 and $1.4 million in Q1 2025.